Oridonin inhibits 4T1 tumor growth by suppressing Treg differentiation via TGF-β receptor

  • 类型:
  • 作者:Jufeng Guo, Tao Chen, Zeyu Ma, Chenxiao Qiao, Fanli Yuan, Xintian Guo, Jian Liu, Yingying Shen, Lei Yu, Aizhai Xiang
  • 期刊:INTERNATIONAL IMMUNOPHARMACOLOGY
  • 阅读原文

The Chinese herbal medicine oridonin has potent anti-inflammatory and antitumor activities. In addition, oridonin treatment effectively suppresses breast cancer growth. However, the underlying mechanisms are poorly defined. Here, we reported that oridonin decreased Treg differentiation in vitro and in vivo. Oridonin inhibition of Treg differentiation was dependent on decreasing TGF-β receptor expression. Oridonin attenuated Tregs' immunosuppressive ability; thus, oridonin did not inhibit CD8+ T cell proliferation very well in vitro. Oridonin greatly delayed the progression of 4T1 tumors in vivo. In addition, oridonin combined with anti-PD-1 activated a robust antitumor immune response and suppressed 4T1 tumor growth. Therefore, our results indicate that oridonin inhibits TNBC growth by modulating Treg differentiation, which provides new directions for the clinical treatment of TNBC.

引用产品已停售或下架

待确认